Market Cap | 6.07M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -19.14M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -31.00% |
Sales | 3.04M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -72.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -88.00% |
Recommedations | - | Quick Ratio | 0.09 | Shares Outstanding | 407.17M | 52W Low Chg | 60.00% |
Insider Own | 50.20% | ROA | -74.70% | Shares Float | 105.57M | Beta | -0.25 |
Inst Own | 25.15% | ROE | - | Shares Shorted/Prior | -/- | Price | 0.01 |
Gross Margin | -4.60% | Profit Margin | - | Avg. Volume | 104,341 | Target Price | - |
Oper. Margin | -731.89% | Earnings Date | Mar 28 | Volume | 129,902 | Change | 0.00% |
SQI Diagnostics Inc., a precision medicine company, discovers, develops, and commercializes rapid diagnostic testing services for healthcare providers, patients, and consumers worldwide. The company also offers TOR-dx, a lung test, which enables the surgeon to assess the health of the donor's lung; and a COVID-19 at-home antibody test kit; the RALI-Dx, a COVID-19 severity triage lab test; and RALI-fast, a COVID-19 severity triage POC test. In addition, it offers microarray tests for protein and antibody testing workflow. The company was founded in 1999 and is headquartered in Toronto, Canada.